APP and atherosclerosis: βCDs have also seen effective in animal models of several other diseases known to involve endocytosis[132]: Alzheimer’s disease (APP),[133] Parkinson’s disease (α-synuclein),[134] and atherosclerosis (LDL),[135, 136] see Fig 3.